Ghent University Academic Bibliography

Advanced

Tailor-made cleavage site attenuates influenza B

Xavier Saelens UGent (2012) EXPERT REVIEW OF VACCINES. 11(2). p.159-161
abstract
Evaluation of: Stech J, Garn H, Herwig A etal. Influenza B virus with modified hemagglutinin cleavage site as a novel attenuated live vaccine. J. Infect. Dis. 204(10), 1483-1490 (2011). Influenza B viruses contribute significantly to human influenza. The circulation of two antigenically divergent lineages of this virus can reduce the efficacy of licensed influenza vaccines. A novel live-attenuated influenza B vaccine candidate has been generated by creating a virus that strictly requires elastase activity for the accurate proteolytic maturation of its hemagglutinin. This mutant influenza B virus grows to high titers in vitro and is strongly attenuated in mice, yet it induces a robust protective immune response in this host. The findings on this tamed influenza B virus and its potential prospects are discussed.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
live-attenuated vaccine, influenza B, hemagglutinin, elastase, proteolytic activation, RECEPTOR-BINDING, VIRUS, HEMAGGLUTININ, VACCINES, TRYPSIN, LIVE, CHILDREN, FUSION, SYSTEM, CELLS
journal title
EXPERT REVIEW OF VACCINES
Expert Rev. Vaccines
volume
11
issue
2
pages
159 - 161
Web of Science type
Article
Web of Science id
000300758700011
JCR category
IMMUNOLOGY
JCR impact factor
4.219 (2012)
JCR rank
33/134 (2012)
JCR quartile
1 (2012)
ISSN
1476-0584
DOI
10.1586/ERV.11.175
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2072180
handle
http://hdl.handle.net/1854/LU-2072180
date created
2012-03-22 09:01:56
date last changed
2012-06-26 14:32:37
@article{2072180,
  abstract     = {Evaluation of: Stech J, Garn H, Herwig A etal. Influenza B virus with modified hemagglutinin cleavage site as a novel attenuated live vaccine. J. Infect. Dis. 204(10), 1483-1490 (2011). 
Influenza B viruses contribute significantly to human influenza. The circulation of two antigenically divergent lineages of this virus can reduce the efficacy of licensed influenza vaccines. A novel live-attenuated influenza B vaccine candidate has been generated by creating a virus that strictly requires elastase activity for the accurate proteolytic maturation of its hemagglutinin. This mutant influenza B virus grows to high titers in vitro and is strongly attenuated in mice, yet it induces a robust protective immune response in this host. The findings on this tamed influenza B virus and its potential prospects are discussed.},
  author       = {Saelens, Xavier},
  issn         = {1476-0584},
  journal      = {EXPERT REVIEW OF VACCINES},
  keyword      = {live-attenuated vaccine,influenza B,hemagglutinin,elastase,proteolytic activation,RECEPTOR-BINDING,VIRUS,HEMAGGLUTININ,VACCINES,TRYPSIN,LIVE,CHILDREN,FUSION,SYSTEM,CELLS},
  language     = {eng},
  number       = {2},
  pages        = {159--161},
  title        = {Tailor-made cleavage site attenuates influenza B},
  url          = {http://dx.doi.org/10.1586/ERV.11.175},
  volume       = {11},
  year         = {2012},
}

Chicago
Saelens, Xavier. 2012. “Tailor-made Cleavage Site Attenuates Influenza B.” Expert Review of Vaccines 11 (2): 159–161.
APA
Saelens, X. (2012). Tailor-made cleavage site attenuates influenza B. EXPERT REVIEW OF VACCINES, 11(2), 159–161.
Vancouver
1.
Saelens X. Tailor-made cleavage site attenuates influenza B. EXPERT REVIEW OF VACCINES. 2012;11(2):159–61.
MLA
Saelens, Xavier. “Tailor-made Cleavage Site Attenuates Influenza B.” EXPERT REVIEW OF VACCINES 11.2 (2012): 159–161. Print.